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Abstract 
The synthesis of a series of imidazole styrylindoles and sulfonyl styrylindoles 
derivatives is described. Evaluation of binding affinity and inhibitory activity against 
CYP24A1 identified the imidazole styrylindoles as potent inhibitors with activity 
greater or comparable with the standard ketoconazole.  
Flexible alignment and docking studies of the inhibitors in the CYP24A1 enzyme 
active site confirmed that complete occupation of the vitamin D access tunnel is 
essential to inhibitory activity, allowing exposure to multiple hydrophobic binding 
interactions and optimal conformation for the interaction of the imidazole nitrogen 
lone pair and the active site haem. 
 
Highlights 
 New series of imidazole styrylindoles and sulfonyl styrylindoles synthesized. 
 Compounds evaluated as inhibitors of 25-hydroxyvitamin D-24-hydroxylase 
(CYP24A1). 
 Imidazole series potent CYP24A1 inhibitors. 
 Computational studies identified key enzyme binding interactions. 
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1. Introduction 
The most biologically active form of vitamin D3, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3, calcitriol, 1) has an important role in the regulation of cell proliferation 
and  differentiation [1] in addition to the key role of calcitriol in the regulation of 
calcium homeostasis and bone metabolism [2], [3]. Serum levels of calcitriol have 
been associated with the prognosis of several cancers, with higher serum levels 
associated with improved prognosis [4], [5], [6] and lower levels associated with an 
increased risk and poorer prognosis [7], [8], [9], [10]. The serum level of calcitriol is 
tightly regulated in a short feedback loop by two cytochrome P450 enzymes, the 1-
hydroxylase CYP27B1 that promotes synthesis of calcitriol and the 24-hydroxylase 
CYP24A1 that inactivates calcitriol by metabolism [11], [12]. Lower calcitriol levels 
is directly linked to high expression of CYP24A1 with increased CYP24A1 levels 
resulting in increased metabolism of calcitriol  significantly reducing the circulating 
calcitriol and therefore the antiproliferative or prodifferentiation effects [13], [14], 
[15], [16]. 
Inhibition of CYP24A1 is therefore an attractive strategy to enhance 
endogenous circulating calcitriol and/or increase the half-life of exogenously 
administered calcitriol or vitamin D therapeutic. Studies using the non-specific CYP 
inhibitors, ketoconazole or liarozole in combination with calcitriol in prostate and 
breast cancer cell lines resulted in increased half-life of calcitriol and enhanced 
antiproliferative effect [17], [18]. Similarly studies using CYP24A1 inhibitors, the 
isoflavone genistein and a novel tetralone derivative, greatly enhanced the apoptotic 
and differention effect of calcitriol in prostate cancer cell lines [19], [20].  
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Figure 1. Structures of natural CYP24A1 substrate calcitriol, standard inhibitor for 
comparison ketoconazole and designed 4- and 5- styrylindole derivatives 
 
Our previous research on non-vitamin D CYP24A1 inhibitors [20], [21], [22] 
indicated the importance of a hydrophobic group or chain to allow complete fill of the 
hydrophobic channel of the CYP24A1 enzyme active site. In the development of the 
azole inhibitors, a styryl group was found to be optimal for inhibitory activity [21] 
(Figure 1) resulting in compounds with activity comparable with the standard 
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inhibitor ketoconazole (Figure 1). Combining the styryl and azole haem binding 
group with an indole group, to mimic the calcitriol C/D ring unit, resulted in the 
design of the herein described indole imidazole series. In addition a series of indole 
sulphonyl derivatives was designed based on the very the promising vitamin D 
sulphonate derivatives [23] (Figure 1).  
 
2. Results  
2.1 Chemistry 
The styrenes (3 and 9) were prepared by Heck reaction of either styrene (2a) 
or 1,3-dimethoxy-5-vinylbenzene (2b) with the bromoindole (1 or 8)  using paladium 
(II) acetate catalyst, tri(o-tolylphosphine) (TOP) as ligand and triethylamine as basic 
medium at 110 
o
C in a sealed tube overnight (Scheme 1) [24]. The indole bromoalkyl 
derivatives with either a lateral three carbon chain (4, 10)  or lateral four carbon chain 
(5, 11) were readily obtained after treatment of the indole (3 or 9) with NaH as base 
and addition of an excess of dibromoalkane followed by column chromatography 
purification. The imidazole products (6, 7, 12 and 13) were obtained in good yield on 
reacting the indole bromoalkyl derivatives (4, 5, 10 and 11) with sodium hydride in 
DMF followed by reaction with imidazole at 45 
o
C overnight (Scheme 1). 
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Scheme 1. Reagents and Conditions: (i) Pd(OAc)2, ToP, Et3N, 110 
o
C, 20 h (ii) NaH, 
DMF, 1,3-dibromopropane or 1,4-dibromobutane, 5 min (iii) NaH, DMF, imidazole, 
45 °C, 1 h then r.t. overnight. 
 
Preparation of the indole sulfonamides (18 and 19) commenced from the the 
indole bromoalkyl derivatives (4 and 5) (Scheme 2). The bromide was displaced with 
azide on treatment with sodium azide and the resulting indole alkylazide derivatives 
(14  and 15) reduced via a Staudinger reaction [25] using triphenylphosphine to give 
the indole alylamines (16 and 17). The final step to prepare the indole sulfonamides 
(18 and 19) invovled reaction of the amines (16 and 17) with p-toluenesulfonyl 
chloride at 0 
o
C for 30 min in the presence of triethylamine. 
To include a compound for testing with a sulfinate bond, 1-(3-
benzenesulfonyl-propyl)-4-styryl-1H-indole (20) was prepared on reaction with 
bromide (4a, n = 3, R = H) with benzene sulfinic acid sodium salt following described 
methodology (Scheme 2) [26], [27]. 
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Scheme 2. Reagents and Conditions: (i) NaN3, DMF, r.t., 5 h (ii) (a) PPh3, THF, r.t. 
1h (b) H2O, 60 
o
C, 2h (iii) TsCl, Et3N, CH2Cl2, 0 °C, 30 min (iv) C6H5SO2Na, DMF, 
r.t., 24 h. 
 
The indole sulfonates (23) were prepared in three steps from the indole styrene 
(3) with introduction of the lateral alcohol chain achieved on reaction of 3 with 
sodium hydride and ethyl-3-bromopropionate and subsequent reduction of the ester 
(21) to the alcohol (22) with LiAlH4. The final sulfonates (23) were readily prepared 
by reaction of the alcohols (22) with p-toluenesulfonyl chloride at room temperature 
for 24 h in the presence of 4-dimethylaminopyridine (DMAP) (Scheme 3). 
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Scheme 3. Reagents and Conditions: (i) NaH, DMF, ethyl-3-bromopropionate, 0 °C 
to r.t., 2 h (ii) LiAlH4, THF, 0 °C 1 h then r.t. 4 h (iii) TsCl, DMAP, CH2Cl2, pyridine, 
r.t., 24 h. 
 
2.2 CYP24A1 Enzyme Inhibition  
The CYP24A1 enzymatic assay followed methodology previously described 
[23], in short human CYP24A1 with an N-terminal fusion to maltose binding protein 
(MBP) was overexpressed in Escherichia coli and purified to homogeneity. The 
hydrolase enzyme was reconstituted in vitro, and the resulting cell-free assay system 
applied in the screening of the compounds to measure Ki and IC50 (Table 1). 
The imidazole styryl indole derivatives 6, 7, 12 and 13 were all potent 
inhibitors of CYP24A1 (Ki 14-37 nM, IC50 0.19-0.52 M) with activity comparable 
with or greater than the standard ketoconazole (Ki 33 nM, IC50 0.47 M) (Table 1). 
The 4-styryl dreivatives with the 4-carbon lateral chain (7) were more active than the 
3-carbon chain derivatives (6), which were of equivalent inhibitory activity to the 5-
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styryl derivates (12 and 13). Substitution of the styryl aromatic ring (R = H or OCH3) 
did not affect the inhibitory activity. 
 
Table 1. IC50 and Ki data for indole imidazole and sulfonyl derivatives vs CYP24A1  
 
Compound IC50 (μM) KI (μM) 
6a 0.36 0.026 ± 0.004 
6b 0.44 0.031 ± 0.004 
7a 0.20 0.014 ± 0.002 
7b 0.19 0.014 ± 0.002 
12 0.52 0.037 ± 0.004 
13 0.52 0.037 ± 0.002 
18a 4.8 0.34 ± 0.02 
18b 10.4 0.73 ± 0.18 
19a 3.3 0.23 ± 0.06 
19b 10.5 0.74 ± 0.03 
20 7.6 0.54 ± 0.07 
23a 9.0 0.64 ± 0.09 
23b 16.9 1.19 ± 0.43 
Ketoconazole 0.47 0.035 
 
The sulfonyl and sulfinyl derivatives (18, 19, 20 and 23) displayed reduced CYP24A1 
inhibitory activity compared with the standard ketoconazole (Table 1). In this series 
the substitution of the styryl aromatic ring (R = H or OCH3) did have an effect with 
the unsubstituted derivatives (18a, 19a, 20 and 23a) displaying greater inhibitory 
activity than the dimethoxy derivatives (18b, 19b and 23b). 
 
2.3 CYP27B1 Enzyme Inhibition and Selectivity  
Inhibition assay of CYP27B1 was performed in a similar way to the 
CYP24A1 assay as previously described [23], and the resulting cell-free assay system 
applied in the screening of the compounds to measure Ki and IC50 (Table 2). 
Compounds with good binding and inhibitory activity against CYP24A1 also 
displayed similar properties against CYP27B1. A small selectivity was observed for 
CYP24A1 with the indole imidazole with a lateral four carbon chain (7a) displaying 
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the best selectivity (selectivity CYP27B1/CYP24A1 = 1.8)  comparable with the 
standard, ketoconazole (selectivity CYP27B1/CYP24A1 = 1.7), although two of the 
derivatives in this series (6b and 13) showed a small selectivity for CYP27B1.  
 
Table 2. IC50 and Ki of indole imidazole derivatives vs CYP24A1 and CYP27B1 and 
selectivity data. 
CYP24A1 CYP27B1 Selectivity 
Compound IC50 (μM) KI (μM) 
IC50 
(μM) 
 
KI (μM) KI 
(CYP27B1/
CYP24A1) 
6a 0.36 0.026 ± 0.004 0.21 0.034 ± 0.005 1.3 
6b 0.44 0.031 ± 0.004 0.14 0.022 ± 0.004 0.71 
7a 0.20 0.014 ± 0.002 0.15 0.025 ± 0.003 1.8 
7b 0.19 0.014 ± 0.002 0.10 0.017 ± 0.004 1.2 
12 0.52 0.037 ± 0.004 0.28 0.046 ± 0.004 1.2 
13 0.52 0.037 ± 0.002 0.15 0.024 ± 0.005 0.65 
Ketoconazole 0.47 0.033  0.36 0.058 1.7 
 
3. Discussion 
The indole-imidazole derivatives were prepared using a 4-step synthetic pathway. The 
six compounds (6a, 6b, 7a, 7b, 12 and 13, Table 1) showed a very interesting activity 
in the CYP24A1 enzymatic assay, which is comparable to our (E)-N-(2-(1H-imidazol-
1-yl)-2-phenylethyl)-4-styrylbenzamides family previously reported [28]. The 
inhibition assay would suggest that the length of the lateral chain and position of the 
styrene on the indole ring are important to activity. The 3 carbon derivatives have 
lower activity, whereas the introduction of an extra carbon on the lateral chain results 
in an increase in inhibitory activity up to 2-fold. Substituting a 5-indole as the central 
core instead of the 4-indole results in a decrease in inhibitory activity.  
In order to provide a rational explanation for the observed enzymatic data, flexible 
alignment and molecular docking studies were performed using MOE 2010 [29] and 
LeadIT2.1.2 [30]. All the molecular modeling studies were performed using a 
CYP24A1 homology model built using a rat CYP24A1 crystal structure [31] as a 
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template and the amino acid sequence of the human isoform following a previous 
published homology model technique [32]. After performing a molecular docking of 
the most promising inhibitor (24: IC50 = 0.11 M; Ki = 7.8 nM; CYP24A1/CYP27B1 
selectivity = 3.3) from the previously reported (E)-N-(2-(1H-imidazol-1-yl)-2-
phenylethyl)-4-styrylbenzamides [28] in the enzyme active site (Figure 2), its active 
binding conformation pose was kept rigid while a flexible alignment was executed 
using a database of the six indole-imidazole derivatives.  
 
 
 
 
 
 
 
 
Figure 2. Structure and Docking of 24: the compound occupies the access tunnel with 
the imidazole ring in an optimal orientation for the interaction with the iron. The 
hydrogen bond between the 3-methoxy group and Gln82 stabilises the molecule in a 
favourable active conformation. 
 
Flexible alignment is a technique which allows determination of the best alignment in 
terms of internal strain and overlap of different molecular features (e.g.: aromatic 
features, H-bond donors/acceptors, etc.) [33]. Using this molecular modeling tool the 
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alignment of the indole-imidazole derivatives with the 24 binding pose conformation 
were evaluated  and an interesting relation was found between the flexible alignment 
results (see Table 3) and the enzymatic inhibition assay data. The most active 
compound in the series, 7b, presents 4 carbons in the lateral chain and the 4-indole as 
central core.  Figure 3A, shows the alignment between 7b (yellow) and 24 (lilac). 
 
 
 
 
 
 
 
 
 
 
Figure 3: Flexible alignment between 24 (lilac) and (A) 7b (yellow), (B) 7a (light 
blue), (C) 6b (green), (D) 6a (white). 
 
The imidazole, the 3,5-dimethoxy phenyl ring and the benzyl portion of the indole 
core of 7b overlap perfectly with the corresponding groups of 24, with 7b perfectly 
spatially aligned with our reference compound. Moreover, as reported in Table 4, this 
conformation has the lowest S value (sum of the internal energy of the ligand [U] and 
the similarity score [F]) and therefore is the best in terms of overlapping score. The 
low S value is due to the good internal energy of the ligand pose (U value) and the 
high similarity score (F value) meaning that the 7b conformation obtained is not 
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forced in the first case and that the two molecules have a high shape/functional group 
similarity in the second case.  
 
Table 3. Scoring results from flexible alignment 
 
Similar observations can be observed for 7a (light blue), a 4-indole derivative with 4 
lateral chain carbons but with no substituent on the aromatic ring. The compound 
overlaps perfectly with 24 (Figure 3B) and its S value is the second in the ranking. 
The absence of the 3,5-dimethoxy substituents results in a decrease in the similarity 
score F with 24 leading to a slightly higher S value. 
 The 3 carbons derivatives 6b (green) and 6a (white), present a higher S value as a 
consequence of the unfavorable visual overlapping (Figure 3C and 3D respectively).  
Both compounds due to the shorter lateral chain do not perfectly overlap with 24 
especially in the imidazole ring moiety. The difference in alignment with inhibitor 24 
between the 4 carbon and the 3 carbon derivatives could be a plausible explanation 
for the CYP24A1 enzymatic assay results.  7b and 7a overlap better with 24 and this 
can influence their disposition in the enzyme active site. The docking studies 
performed confirmed the importance of the length of the lateral chain.  All the 
compounds reach the enzyme active site through the vitamin D access tunnel and are 
exposed to multiple hydrohobic residues (Ile131, Trp134, Met246, Phe249, Thr394, 
Entry mol U (kcal/mol) F S dU 
1 7b 34.3428 -169.6129 -135.2701 0.0 
2 7a 26.3473 -153.5406 -127.1933 0.0 
3 6b 32.7516 -148.6960 -115.9444 0.0 
4 6a 25.0259 -131.2711 -106.2452 0.0 
5 13 24.4710 -125.4641 -100.9931 0.0 
6 12 23.3696 -119.7692 -96.4266 0.0 
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Thr395, Gly499, Tyr500) which have been reported to have multiple hydrophobic 
interactions with calcitriol [31]. This disposition allows the imidazole ring to be 
optimally positioned for the interaction between its nitrogen lone pair and the haem 
iron. 7b is disposed in the active site in the same manner as 24, occupies the full 
length of the enzyme channel and forms a H-bond between its 3-methoxy group and 
Gln82 as found for our reference compound (Figure 4).  
 
 
 
 
 
 
 
 
 
Figure 4: Docking of 7b: the compound is able to entirely occupy the active site 
thanks to the 4-carbon lateral chain 
 
Docking studies of 6b and 6a, showed the two molecules orientated in the right 
position with the imidazole ring perpendicular to the iron, but due to the lack of one 
carbon on the lateral chain they are not able to entirely occupy the active site (far 
from Gln 82) and their interaction with the CYP24A1 could be less strong than the 4-
carbon lateral chain derivatives influencing their inhibition activity (Figure 5). 
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Figure 5. Docking of 6b and 6a: the compounds are not able to entirely occupy the 
active site access tunnel as consequence of the shorter lateral chain. 
 
The 5-indole derivatives 13 (green) and 12 (red) showed the lowest activity among 
this indole-imidazole series. The flexible alignment results showed both molecules do 
not completely overlap with 24 (Figure 6) especially in the important imidazole ring 
region giving a low S value as a final score. 
 
 
 
 
 
 
 
Figure 6: Flexible alignment between 24 (lilac) and 13 (green) and 12 (red): no 
optimal spatial overlapping was found in the imidazole ring region. 
 
The docking studies of these two derivatives confirmed our initial deduction and the 
possible connection between the spatial alignment with 24 and the capacity to entirely 
sit in the enzyme active site. 13 was not able to occupy the active site due to its 
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structural flexibility conferred by the presence of the stryryl ring in position 5 instead 
of 4 (Figure 7). As previously mentioned, the inability to accommodate the entire 
active site can result in a decrease of CYP24A1 enzymatic inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Docking of 13: the molecule does not occupy entirely the active site due to 
its structural flexibility conferred by the styryl ring in position 5 of the central indole 
core. 
 
The replacement of the imidazole in both the indole-sulfonate and indole-sulfonamide 
series resulted in a notable decrease in inhibitory activity. These results underline the 
key role of the imidazole ring in the binding to the CYP24A1 haem group [34], [35]. 
In fact, the higher structural similarity among these three families suggests that the 
decrease in activity in these two last series of compounds is a consequence of the 
replacement of the imidazole by the sulfonate or sulfonamide moiety. The interaction 
of the indole-sulfonate and the indole-sulfonamide derivatives with the haem iron is 
not strong enough resulting in reduced inhibitory activity. A rational explanation 
could be found in the different availability of the electron lone pair of the imidazole 
nitrogen in one case and of the sulfonyl-sulfonamidic oxygen in the other case. The 
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imidazole lone pair could be more available for the interaction with the haem group 
making the imidazole-Fe a strong interaction. On the other hand, the possibility to 
share the lone pair between the two oxygen atoms of the sulfonyl-sulfonamide group 
makes the oxygen-Fe interaction weaker resulting in the important decrease of the 
CYP24A1 inhibitory activity. The use of the more stable sulfonamide instead of the 
sulfonte group gave the desired result with activity improved by 2-3 fold but not 
comparable with the indole-imidazole family. 
 
4. Conclusions 
We have developed methods for the preparation of novel styrylindoles (imidazole, 
sulfonate and sulfonamide series). The thirteen new styrylindoles have been assayed 
for the inhibition of CYP24A1 and CYP27B1. The imidazole styrylindoles were the 
most potent CYP24A1 inhibitors with IC50 values from 0.19 - 0.52 M comparable 
with the CYP inhibitor ketoconazole (IC50 0.47M). The sulfonate and sulfonamides 
displayed only weak CYP24A1 inhibitory activity indicating the importance of the 
imidazole azole group in interacting with the active site haem moiety. A four carbon 
lateral chain was optimal resulting in complete occupation of the vitamin D access 
tunnel and allowing exposure to multiple hydrophobic binding interactions and 
optimal conformation for the interaction of the imidazole nitrogen lone pair and the 
active site haem. A small selectivity for CYP24A1 over CYP27B1 comparable with 
ketoconazole (CYP27B1/CYP24A1 7a = 1.8, ketoconazole = 1.7) was observed. 
The challenge in the development of CYP24A1 inhibitors is achieving selectivity 
between CYP24A1 and CYP27B1. In the absence of an available crystal structure of 
CYP27B1 it is essential to develop a reliable homology model to allow exploitation of 
any differences between the active sites of CYP24A1 and CYP27B1, however with 
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the similarity of the two substrates, 1,25(OH)2D3 and 25(OH) D3 respectively, any 
differences are likely to be subtle. This is the current focus of our investigations using 
the styrylindoles (e.g. 7a) and styrylbenzamides (e.g. 24) as lead compounds for 
further development. 
 
5. Experimental 
5.1. Materials and Methods 
1,25(OH)2D3 and 25(OH)D3 were purchased from SAFC-Pharma (Madison, 
WI). Human MBP-CYP24A1, mouse CYP27B1, bovine adrenodoxin (Adx), and 
adrenodoxin reductase (AdR) were purified as described previously [14]. All solvents 
used for chromatography were HPLC grade from Fisher Scientific (UK).  
1
H and 
13
C NMR spectra were recorded with a Bruker Avance DPX500 spectrometer 
operating at 500 and 125 MHz, with Me4Si as internal standard. Mass spectra were 
determined by the EPSRC mass spectrometry centre (Swansea, UK). Flash column 
chromatography was performed with silica gel 60 (230-400mesh) (Merck) and TLC 
was carried out on precoated silica plates (kiesel gel 60 F254, BDH). Compounds were 
visualised by illumination under UV light (254 nm) or by the use of vanillin stain 
followed by charring on a hotplate. Melting points were determined on an 
electrothermal instrument and are uncorrected. All solvents were dried prior to use 
and stored over 4Å molecular sieves, under nitrogen. All compounds were more than 
95% pure. 
 
5.1.1 General method for the preparation of styryl-1H-indoles 3 and 9. Styrene 
(2a) or 1,3-dimethoxy-5-vinylbenzene (2b) (10 mmol), 4-bromoindole (1) or 5-
bromoindole (8) (10 mmol), and triethylamine (20 mmol) were heated in the presence 
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of tri(o-tolylphosphine) (TOP, 0.3 mmol) and palladium (II) acetate (0.05 mmol) in a 
sealed glass tube at 110°C for 5 h. On completion, water (10 mL) was added. The 
product was portioned between CH2Cl2 (100 mL) and water (100 mL), then the 
organic layer was dried over MgSO4 and the solvent evaporated under vacuum. The 
product was isolated by flash column chromatography (petroleum ether-EtOAc 100:0 
v/v increasing to 90:10 v/v). 
5.1.1.1. 4-Styryl-1H-indole (3a, R = H). Obtained in 80% yield as a green solid. 
M.p. 126-128 
o
C. TLC (7:3 Petroleum ether/EtOAc, Rf = 0.57). 
1
H NMR (CDCl3): 
8.30 (bs, 1H, NH), 7.63 (d, J = 8.2 Hz, 2H, Ar), 7.59 (d, J = 16.3 Hz, 1H, alkene), 
7.33 (d, J = 7.4 Hz, 2H, Ar), 7.30 (d, J = 16.1 Hz, 1H, alkene), 7.20-7.26 (m, 4H, Ar 
and indole), 7.03 (m, 1H, Ar), 6.72 (s, 1H, indole). 
13
C NMR (CDCl3):  136.8, 
135.1, 128.6, 125.1 (C, Ar), 128.2, 127.5, 126.3, 126.2, 125.4, 121.6, 119.3, 113.6, 
109.5, 100.0 (CH, Ar and alkene). Anal. Calcd for C16H13N 0.1H2O (221.08692): C, 
86.92; H, 6.02; N, 6.34. Found: C, 87.10; H, 5.86; N, 6.40. 
5.1.1.2. 4-(3,5-Dimethoxystyryl)-1H-indole (3b, R = OCH3). Obtained in 65% yield 
as a green-grey solid. M.p. 96-98 
o
C. TLC (7:3 Petroleum ether/EtOAc, Rf = 0.50). 
1
H NMR (CDCl3): 8.27 (bs, 1H, NH), 7.53 (d, J = 16.3 Hz, 1H, alkene), 7.39 (d, J = 
7.3 Hz, 1H, Ar), 7.36 (d, J = 8.1 Hz, 1H, Ar), 7.31 (t, J = 2.9 Hz, 1H, indole), 7.23-
7.28 (m, 2H, Ar and alkene), 6.87 (m, 1H, indole), 6.78 (d, J = 2.2 Hz, 2H, Ar), 6.45 
(t, J = 2.2 Hz, 1H, Ar), 3.88 (s, 6H, 2 x OCH3). 
13
C-NMR (CDCl3): 161.0 (C), 
140.0, 136.2, 129.5, 126.3 (C, Ar), 129.3, 127.9, 124.4, 122.2, 117.7, 110.6, 104.6, 
101.3, 99.7 (CH, Ar and alkene), 55.4 (2 x OCH3). EI-HRMS (M + H)
+
 found 
280.1332, calculated for C18H18NO2 280.1335.  
5.1.1.3. 5-Styryl-1H-indole (9). Obtained in 49% yield as a pale green solid. M.p. 
152-154 
o
C. TLC (7:3 Petroleum ether/EtOAc, Rf = 0.62). 
1
H NMR (CDCl3): 8.15 
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(bs, 1H, NH), 7.80 (s, 1H, Ar), 7.57 (d, J = 7.4 Hz, 2H, Ar), 7.49 (dd, Jx,a = 1.7 Hz, 
Jx,b = 8.7  Hz, 1H, Arx), 7.37-7.41 (m, 3H, Ar and indole), 7.25-7.31 (m, 2H, Ar and 
alkene), 7.23 (t, J = 2.8 Hz, 1H, Ar), 7.12 (d, J = 16.3 Hz, 1H, alkene), 6.60 (m, 1H, 
indole). 
13
C-NMR (CDCl3): 138.0, 135.6, 129.6, 128.2 (C, Ar), 13.0, 128.6, 126.9, 
126.2, 126.1, 124.7, 120.7, 119.5, 111.2, 103.0 (CH, Ar and alkene). Anal. Calcd for 
C16H13N 0.1H2O (221.08692): C, 86.92; H, 6.02; N, 6.34. Found: C, 87.07; H, 6.28; 
N, 6.44. 
 
5.1.2 General method for the preparation of styryl-1-bromoalkyl-1H-indoles 4, 5, 
10 and 11. The different 4/5-(3,5-unsubstituted/substituted styryl)-1H-indole (3 or 9) 
(7 mmol) and NaH  (60% dispersion in mineral oil) (21 mmol) in dry DMF (10 mL) 
were cooled to 0˚C using an ice bath and stirred for 5 min. 1,3-Dibromopropane or  
1,4-dibromobutane (70 mmol) was added and the reaction mixture was stirred for 10 
min. On completion, the solvent was evaporated under reduced pressure and the 
residue was dissolved in CH2Cl2 (100 mL), washed with water (2 x 50 mL) and dried 
over MgSO4. The organic layer was then evaporated to dryness and the residue was 
purified by flash column chromatography to obtain the pure product. 
5.1.2.1. 1-(3-Bromopropyl)-4-styryl-1H-indole (4a, R = H). Purified by flash 
column chromatography eluting with petroleum ether-diethyl ether 100:0 v/v 
increasing to 99:1 v/v. Obtained in 50% yield as a thick yellow oil. TLC (3:1 
Petroleum ether/EtOAc, Rf = 0.73). 
1
H NMR (CDCl3): 7.61 (d, J = 7.3 Hz, 2H, Ar), 
7.55 (d, J = 16.3 Hz, 1H, alkene), 7.39-7.43 (m, 3H, Ar), 7.26-7.36 (m, 4H, Ar and 
alkene), 7.25 (d, J = 3.0 Hz, 1H, indole), 6.83 (d, J = 3.0 Hz, 1H, indole), 4.40 (t, J = 
6.4 Hz, 2H, CH2), 3.34 (t, J = 6.1 Hz, 2H, CH2), 2.39 (m, 2H, CH2). 
13
C-NMR 
(CDCl3): 137.9, 136.3, 130.1, 129.9 (C, Ar), 129.5, 128.6, 128.3, 127.4, 127.1, 
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126.5, 121.9, 117.3, 108.7, 100.1 (CH, Ar and alkene), 44.1, 32.7, 30.4 (CH2). EI-
HRMS (M + H)
+
 found 341.07795, calculated for C19H19BrN 341.07791. 
5.1.2.2. 4-(3,5-Dimethoxystyryl)-1-(3-bromopropyl)-1H-indole (4b, R = OCH3). 
Purified by flash column chromatography eluting with petroleum ether-EtOAc 100:0 
v/v increasing to 95:5 v/v. Obtained in 66% yield as a yellow oil. TLC (3:1 Petroleum 
ether/EtOAc, Rf = 0.72). 
1
H NMR (CDCl3): 7.53 (d, J = 16.3 Hz, 1H, alkene), 7.39 
(d, J = 7.3 Hz, 1H, Ar), 7.34 (d, J = 8.1 Hz, 1H, Ar), 7.23-7.28 (m, 3H, Ar, indole and 
alkene), 6.83 (m, 1H, indole), 6.77 (d, J = 2.3 Hz, 2H, Ar), 6.44 (t, J = 2.3 Hz, 1H, 
Ar), 4.38 (t, J = 6.3 Hz, 2H, CH2),  3.88 (s, 6H, 2 x OCH3), 3.34 (t, J = 6.1 Hz, 2H, 
CH2), 2.39 (m, 2H, CH2). 
13
C-NMR (CDCl3): 161.0 (C), 140.0, 136.3, 129.9, 127.1 
(C, Ar), 129.4, 128.3, 127.7, 121.9, 117.4, 108.8, 104.6, 101.1, 99.7 (CH, Ar and 
alkene), 55.4 (2 x OCH3). EI-HRMS (M + H)
+
 found 400.0911, calculated for 
C21H23BrNO2 400.0907. 
5.1.2.3. 1-(4-Bromobutyl)-4-styryl-1H-indole (5a, R = H). Purified by flash column 
chromatography eluting with petroleum ether-EtOAc 100:0 v/v increasing to 90:10 
v/v. Obtained in 86% yield as a thick yellow oil. TLC (3:1 Petroleum ether/EtOAc, Rf 
= 0.73). 
1
H NMR (CDCl3): 7.64 (d, J = 7.4 Hz, 2H, Ar), 7.58 (d, J = 16.2 Hz, 1H, 
alkene), 7.42-7.45 (m, 3H, Ar), 7.30-7.37 (m, 4H, Ar and alkene), 7.19 (d, J = 3.3 Hz, 
1H, indole), 6.85 (d, J = 3.3 Hz, 1H, indole), 4.21 (t, J = 6.7 Hz, 2H, CH2), 3.41 (t, J = 
6.5 Hz, 2H, CH2), 2.06 (m, 2H, CH2), 1.89 (m, 2H, CH2). 
13
C-NMR (CDCl3): 138.0, 
136.4, 130.0, 127.4 (C, Ar), 129.4, 128.7, 128.1, 127.5, 127.0, 126.5, 121.8, 117.2, 
108.7, 99.9 (CH, Ar and alkene), 45.6, 32.9, 29.9, 28.8 (CH2). EI-HRMS (M + H)
+
 
found 354.0857, calculated for C20H21BrN 354.0852. 
5.1.2.4. 4-(3,5-Dimethoxystyryl)-1-(4-bromobutyl)-1H-indole (5b, R = OCH3). 
Purified by flash column chromatography eluting with petroleum ether-EtOAc 100:0 
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v/v increasing to 90:10 v/v. Obtained in 69% yield as a thick yellow oil. TLC (3:1 
Petroleum ether/EtOAc, Rf = 0.55). 
1
H NMR (CDCl3): 7.51 (d, J = 16.4 Hz, 1H, 
alkene), 7.38 (d, J = 7.3 Hz, 1H, Ar), 7.30 (d, J = 8.0 Hz, 1H, Ar), 7.22-7.31 (m, 2H, 
Ar and alkene), 7.18 (d, J = 3.2 Hz, 1H, indole), 6.82 (d, J = 3.2 Hz, 1H, indole), 6.77 
(d, J = 2.2 Hz, 2H, Ar), 6.44 (t, J = 2.2 Hz, 1H, Ar), 4.21 (t, J = 6.8 Hz, 2H, CH2),  
3.88 (s, 6H, 2 x OCH3), 3.40 (t, J = 6.6 Hz, 2H, CH2), 2.06 (m, 2H, CH2), 1.89 (m, 
2H, CH2). 
13
C-NMR (CDCl3): 161.0 (C), 140.0, 136.4, 129.8, 127.0 (C, Ar), 129.3, 
127.9, 127.7, 121.8, 117.3, 108.8, 104.6, 99.8, 99.7 (CH, Ar and alkene), 55.4 (2 x 
OCH3), 45.6, 32.9, 29.9, 28.8 (CH2). EI-HRMS (M)
+
 found 413.0990, calculated for 
C22H24BrNO2 413.0985. 
5.1.2.5. 1-(3-Bromopropyl)-5-styryl-1H-indole (10). Purified by flash column 
chromatography eluting with petroleum ether-diethyl ether 100:0 v/v increasing to 
99:1 v/v. Obtained in 46% yield as a white solid. M.p. 78-80 
o
C. TLC (9:1 Petroleum 
ether/EtOAc, Rf = 0.50). 
1
H NMR (CDCl3): 7.78 (s, 1H, Ar), 7.56 (d, J = 7.2 Hz, 
2H, Ar), 7.50 (dd, Jx,a = 1.6 Hz, Jx,b = 8.6  Hz, 1H, Arx), 7.37-7.42 (m, 3H, Ar), 7.23-
7.30 (m, 2H, Ar and alkene), 7.17 (d, J = 3.1 Hz, 1H, indole), 7.11 (d, J = 16.3 Hz, 
1H, alkene), 6.54 (d, J = 3.2 Hz, 1H, indole), 4.36 (t, J = 6.4 Hz, 2H, CH2), 3.34 (t, J 
= 6.1 Hz, 2H, CH2), 2.39 (m, 2H, CH2). 
13
C-NMR (CDCl3): 138.0, 135.7, 129.3, 
129.1 (C, Ar), 129.9, 128.6, 128.2, 126.9, 126.2, 126.1, 120.3, 119.8, 109.5, 102.0 
(CH, Ar and alkene), 44.1, 32.8, 30.4 (CH2). Anal. Calcd for C19H18BrN (340.256): C, 
67.07; H, 5.33; N, 4.11. Found: C, 66.73; H, 5.75; N, 4.08.  
5.1.2.5. 1-(4-Bromobutyl)-5-styryl-1H-indole (11). Purified by flash column 
chromatography eluting with petroleum ether-EtOAc 100:0 v/v increasing to 98:2 v/v. 
Obtained in 84% yield as a yellow wax. TLC (9:1 Petroleum ether/EtOAc, Rf = 0.44). 
1
H NMR (CDCl3): 7.78 (s, 1H, Ar), 7.56 (d, J = 7.5 Hz, 2H, Ar), 7.50 (dd, Jx,a = 1.3 
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Hz, Jx,b = 8.6  Hz, 1H, Arx), 7.38-7.42 (m, 2H, Ar), 7.34 (d, J = 8.6 Hz, 1H, Ar) 7.24-
7.30 (m, 2H, Ar and alkene), 7.12 (d, J = 16.3 Hz, 1H, alkene), 7.11 (d, J = 3.2 Hz, 
1H, indole), 6.54 (d, J = 3.2 Hz, 1H, indole), 4.19 (t, J= 6.9 Hz, 2H, CH2), 3.41 (t, J= 
6.6 Hz, 2H, CH2), 2.00 (m, 2H, CH2), 1.89 (m, 2H, CH2) . 
13
C-NMR (CDCl3): 
138.0, 135.8, 129.1, 129.0 (C, Ar), 130.0, 128.6, 128.2, 126.9, 126.2, 126.0, 120.2, 
119.8, 109.5, 101.8 (CH, Ar and alkene), 45.6, 32.9, 29.9, 28.8 (CH2). EI-HRMS (M 
+ H)
+
 found 354.0849, calculated for C20H21BrN 354.0852. 
 
5.1.3 General method for the preparation of imidazoles 6, 7, 12 and 13. A 
suspension of NaH (60% dispersion in mineral oil) (6 mmol) in dry DMF (15 mL) 
was stirred and heated at 60˚C for 5 min. Imidazole (6 mmol) was added and the 
reaction mixture was heated at 60˚C for 1 h. The reaction mixture was cooled to room 
temperature and the styryl-1-bromoalkyl-1H-indole (4, 5, 10 or 11) (3 mmol) was 
added. The reaction mixture was heated at 60˚C overnight and then hydrolysed by 
adding H2O (100 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL); 
the organic layers were collected and dried over MgSO4. The solvent was then 
evaporated to dryness and the residue was purified by flash column chromatography 
(petroleum ether-EtOAc 50:50 v/v then CH2Cl2-MeOH 100:0 v/v increasing to 98:2 
v/v) to obtain the pure desired product. 
5.1.3.1. 1-[3-(1H-Imidazol-1-yl)propyl]-4-styryl-1H-indole (6a, R = H). Obtained 
in 72% yield as a yellow glue. TLC (9:1 CH2Cl2/MeOH, Rf = 0.31). 
1
H NMR 
(CDCl3): 7.61 (d, J = 7.4 Hz, 2H, Ar), 7.54 (d, J = 16.1 Hz, 1H, alkene), 7.48 (s, 
1H, imid), 7.39-7.42 (m, 3H, Ar), 7.24-7.34 (m, 4H, Ar and alkene), 7.19 (d, J = 8.4 
Hz, 1H, Ar), 7.14 (s, 1H, imid), 7.12 (d, J = 3.2 Hz, 1H, indole), 6.93 (s, 1H, imid), 
6.86 (d, J = 3.1 Hz, 1H, indole), 4.17 (t, J = 6.6 Hz, 2H, CH2), 3.91 (t, J = 7.0 Hz, 2H, 
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CH2), 2.39 (m, 2H, CH2). 
13
C-NMR (CDCl3): 137.8, 136.3, 130.2, 127.1 (C, Ar), 
137.2, 130.0, 129.6, 128.6, 127.7, 127.5, 126.5, 122.1, 118.5, 117.4, 108.5, 102.4, 
100.5 (CH, Ar and alkene), 43.8, 43.0, 31.0 (CH2). EI-HRMS (M + H)
+
 found 
328.1807, calculated for C22H22N3 328.1808. 
5.1.3.2. 1-[3-(1H-Imidazol-1-yl)propyl]-4-(3,5-dimethoxystyryl)-1H-indole (6b, R 
= OCH3). Obtained in 72% yield as a yellow-orange glue. TLC (3:1 Petroleum 
ether/EtOAc, Rf = 0.14).  
1
H NMR (CDCl3): 7.51 (d, J = 16.3 Hz, 1H, alkene), 7.48 
(s, 1H, imid), 7.4 0 (d, J = 7.3 Hz, 1H, Ar), 7.19-7.26 (m, 3H, Ar and alkene), 7.14 (s, 
1H, imid), 7.12 (d, J = 3.1 Hz, 1H, indole), 6.93 (s, 1H, imid), 6.85 (d, J = 3.1 Hz, 1H, 
indole), 6.77 (d, J = 2.2 Hz, 2H, Ar), 6.44 (t, J = 2.3 Hz, 1H, Ar), 4.17 (t, J = 6.7 Hz, 
2H, CH2), 3.91 (t, J = 6.8 Hz, 2H, CH2), 3.88 (s, 6H, 2 x OCH3), 2.39 (m, 2H, CH2). 
13
C-NMR (CDCl3): 161.0 (C), 139.9, 136.3, 130.0, 127.5 (C, Ar), 137.2, 129.6, 
128.2, 127.8, 122.1, 118.5, 117.6, 108.6, 106.2, 104.6, 100.5, 99.8 (CH, Ar and 
alkene), 55.4 (2 x OCH3), 43.8, 43.0, 31.0 (CH2). EI-HRMS (M + H)
+
 found 
388.2018, calculated for C24H26N3O2 388.2020. 
5.1.3.3. 1-[4-(1H-Imidazol-1-yl)butyl]-4-styryl-1H-indole (7a, R = H). Obtained in 
67% yield as a thick yellow oil. TLC (9:1 CH2Cl2/MeOH, Rf = 0.40). 
1
H NMR 
(CDCl3): 7.60 (d, J = 7.5 Hz, 2H, Ar), 7.58 (d, J = 16.3 Hz, 1H, alkene), 7.38-7.41 
(m, 4H, Ar and imid), 7.23-7.33 (m, 5H, Ar, alkene and imid), 7.13 (d, J = 3.2 Hz, 
1H, indole), 7.06 (s, 1H, imid), 6.82 (d, J = 3.2 Hz, 1H, indole), 4.16 (t, J = 6.5 Hz, 
2H, CH2), 3.85 (t, J = 6.9 Hz, 2H, CH2), 1.85 (m, 2H, CH2), 1.78 (m, 2H, CH2). 
13
C-
NMR (CDCl3): 137.9, 136.3, 130.1, 127.0 (C, Ar), 137.0, 129.6, 129.5, 128.6, 
127.8, 127.4, 127.1, 126.4, 121.9, 118.6, 117.2, 108.6, 100.1 (CH, Ar and alkene), 
46.4, 45.9, 28.6, 27.2 (CH2). EI-HRMS (M + H)
+
 found 342.1959, calculated for 
C23H24N3 342.1965. 
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5.1.3.4. 1-[4-(1H-Imidazol-1-yl)butyl]-4-(3,5-dimethoxystyryl)-1H-indole (7b, R = 
OCH3). Obtained in 75% yield as a thick yellow oil. TLC (9:1 CH2Cl2/MeOH, Rf = 
0.48).  
1
H NMR (CDCl3): 7.50 (d, J = 16.1 Hz, 1H, alkene), 7.37-7.40 (m, 2H, Ar 
and imida.), 7.23-7.26 (m, 3H, Ar and alkene), 7.13 (d, J = 3.3 Hz, 1H, indole), 7.06 
(s, 1H, imid), 6.83 (s, 1H, imid), 6.81 (d, J = 3.3 Hz, 1H, indole), 6.76 (d, J = 2.2 Hz, 
2H, Ar), 6.44 (t, J = 2.2 Hz, 1H, Ar), 4.17 (t, J = 6.3 Hz, 2H, CH2), 3.87 (s, 6H, 2 x 
OCH3), 3.85 (t, J = 6.7 Hz, 2H, CH2), 1.86 (m, 2H, CH2), 1.78 (m, 2H, CH2). 
13
C-
NMR (CDCl3): 161.0 (C), 139.9, 136.3, 129.9, 127.9 (C, Ar), 137.0, 129.6, 129.4, 
127.6, 127.0, 121.9, 118.6, 117.4, 108.7, 104.6, 100.1, 99.8 (CH, Ar and alkene), 55.4 
(2 x OCH3), 46.4, 45.9, 28.6, 27.2 (CH2). EI-HRMS (M + H)
+
 found 402.2173, 
calculated for C25H28N3O2 402.2176. 
5.1.3.5. 1-[3-(1H-Imidazol-1-yl)propyl]-5-styryl-1H-indole (12). Obtained in 83% 
yield as a white solid. TLC (9:1 CH2Cl2/MeOH, Rf = 0.61). M.p. 116-118 
o
C.  
1
H 
NMR (CDCl3): 7.78 (s, 1H, Ar), 7.56 (d, J = 7.3 Hz, 2H, Ar), 7.45-7.52 (m, 2H, 
Ar), 7.38-7.40 (m, 2H, Ar), 7.22-7.28 (m, 3 H, Ar, imid and alkene), 7.15 (s, 1H, 
imid),  7.11 (d, J = 16.3 Hz, 1H, alkene), 7.04 (d, J = 3.1 Hz, 1H, indole), 6.92 (s, 1H, 
imid),  6.57 (d, J = 3.1 Hz, 1H, indole), 4.13 (t, J = 6.6 Hz, 2H, CH2), 3.90 (t, J = 6.8 
Hz, 2H, CH2), 2.39 (m, 2H, CH2). 
13
C-NMR (CDCl3): 137.9, 135.6, 129.5, 129.1 
(C, Ar), 137.2, 130.0, 128.6, 128.0, 127.0, 126.3, 126.2, 120.6, 119.9, 118.6, 109.4, 
102.4 (CH, Ar and alkene), 43.8, 42.9, 31.0 (CH2). Anal. Calcd for C22H21N3 0.5H2O 
(336.1814): C, 78.59; H, 6.32; N, 12.49. Found: C, 78.56; H, 6.70; N, 12.48. 
5.1.3.6. 1-[4-(1H-Imidazol-1-yl)butyl]-5-styryl-1H-indole (13). Obtained in 67% 
yield as a white solid. TLC (9:1 CH2Cl2/MeOH, Rf = 0.50). M.p. 114-116 
o
C.  
1
H 
NMR (CDCl3): 7.77 (s, 1H, Ar), 7.55 (d, J = 7.5 Hz, 2H, Ar), 7.48 (dd, Jx,a = 1.5 Hz, 
Jx,b = 8.6  Hz, 1H, Arx), 7.36-7.42 (m, 3H, Ar and alkene), 7.30 (d, J = 8.6 Hz, 1H, 
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Ar), 7.24-7.28 (m, 2H, Ar and imid), 7.10 (d, J = 16.3 Hz, 1H, alkene), 7.07 (s, 1H, 
imid),  7.05 (d, J = 3.1 Hz, 1H, indole), 6.84 (s, 1H, imid),  6.53 (d, J = 3.1 Hz, 1H, 
indole), 4.15 (t, J = 6.4 Hz, 2H, CH2), 3.86 (t, J = 6.9 Hz, 2H, CH2), 1.86 (m, 2H, 
CH2), 1.79 (m, 2H, CH2). 
13
C-NMR (CDCl3): 138.0, 135.7, 129.2, 129.0 (C, Ar), 
137.0, 129.9, 129.7, 128.6, 128.1, 126.9, 126.2, 126.1, 120.3, 119.9, 118.6, 109.4, 
102.0 (CH, Ar and alkene), 46.4, 45.8, 28.6, 27.2 (CH2). Anal. Calcd for C23H23N3 
0.1H2O (342.99077): C, 80.54; H, 6.81; N, 12.25. Found: C, 80.39; H, 7.39; N, 12.20. 
 
5.1.4 General method for the preparation of azides 14 and 15. Sodium azide (4.5 
mmol) was added to a solution of styryl-1-bromoalkyl-1H-indole (4 or 5) (3 mmol) in 
DMF (3 mL). The resulting green reaction mixture was stirred at room temperature 
for 5 h then H2O (20 mL) was added and the aqueous layer extracted with EtOAc (3 x 
20 mL). The combined organic phase was washed with brine (30 mL), dried over 
MgSO4 and evaporated in vacuo to give the pure product as a glue. 
5.1.4.1. 1-(3-Azido-propyl)-4-styryl-1H-indole (14a, R = H). Obtained in 82% yield 
as an orange glue. TLC (4:1 Petroleum ether/EtOAc, Rf = 0.50). 
1
H NMR (CDCl3): 
7.62 (d, J = 7.3 Hz, 2H, Ar), 7.55 (d, J = 16.4 Hz, 1H, alkene), 7.39-7.43 (m, 3H, 
Ar), 7.26-7.35 (m, 4H, Ar and alkene), 7.19 (d, J = 3.1 Hz, 1H, indole), 6.84 (d, J = 
3.0 Hz, 1H, indole), 4.29 (t, J = 6.6 Hz, 2H, CH2), 3.29 (t, J = 6.4 Hz, 2H, CH2), 2.12 
(m, 2H, CH2). 
13
C-NMR (CDCl3): 137.9, 136.3, 130.1, 127.0 (C, Ar), 129.5, 128.1, 
127.4, 127.1, 126.5, 122.0, 117.3, 108.6, 100.2 (CH, Ar and alkene), 48.3, 43.2, 29.3 
(CH2). EI-HRMS (M + H)
+
 found 303.1608, calculated for C19H19N4 303.1604. 
5.1.4.2. 1-(3-Azido-propyl)-4-(3,5-dimethoxystyryl)-1H-indole (14b, R = OCH3). 
Obtained in 72% yield as an orange glue. TLC (4:1 Petroleum ether/EtOAc, Rf = 
0.50). 
1
H NMR (CDCl3): 7.50 (d, J = 16.2 Hz, 1H, alkene), 7.36 (d, J = 7.2 Hz, 1H, 
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Ar), 7.21-7.29 (m, 3H, Ar, and alkene), 7.16 (d, J = 3.2 Hz, 1H, indole), 6.81 (dd, Jx,a 
= 0.8 Hz, Jx,b = 2.6  Hz, 1H, indole) 6.75 (d, J = 2.2 Hz, 2H, Ar), 6.42 (t, J = 2.2 Hz, 
1H, Ar), 4.23 (t, J = 6.7 Hz, 2H, CH2),  3.85 (s, 6H, 2 x OCH3), 3.24 (t, J = 6.2 Hz, 
2H, CH2), 2.07 (m, 2H, CH2). 
13
C-NMR (CDCl3): δ 161.0 (C), 139.9, 136.3, 129.7, 
127.0 (C, Ar), 129.3, 128.2, 127.6, 121.9, 117.4, 108.8, 104.6, 100.4, 99.7 (CH, Ar 
and alkene), 55.3 (2 x OCH3), 48.3, 43.1, 29.3 (CH2). EI-HRMS (M + H)
+
 found 
363.1817, calculated for C21H23BrN4O2 363.1816. 
5.1.4.3. 1-(4-Azido-butyl)-4-styryl-1H-indole (15a, R = H). Obtained in 86% yield 
as a yellow glue. TLC (4:1 Petroleum ether/EtOAc, Rf = 0.57). 
1
H NMR (CDCl3): 
7.63 (d, J = 7.4 Hz, 2H, Ar), 7.58 (d, J = 16.2 Hz, 1H, alkene), 7.41-7.44 (m, 3H, 
Ar), 7.35 (d, J = 16.2 Hz, 1H, alkene), 7.26-7.33 (m, 3H, Ar), 7.10 (d, J = 3.1 Hz, 1H, 
indole), 6.85 (d, J = 3.1 Hz, 1H, indole), 4.18 (t, J = 6.97 Hz, 2H, CH2), 3.28 (t, J = 
6.8 Hz, 2H, CH2), 1.95 (m, 2H, CH2), 1.61 (m, 2H, CH2). 
13
C-NMR (CDCl3): 138.0, 
136.4, 130.0, 127.4 (C, Ar), 129.3, 128.7, 128.1, 127.5, 127.0, 126.5, 121.5, 117.2, 
108.8, 99.3 (CH, Ar and alkene), 45.6, 32.9, 29.9, 28.8 (CH2). EI-HRMS (M + H)
+
 
found 317.1764, calculated for C20H21N4 317.1761. 
5.1.4.4. 1-(4-Azido-butyl)-4-(3,5-dimethoxystyryl)-1H-indole (15b, R = OCH3). 
Obtained in 57% yield as an orange glue. TLC (4:1 Petroleum ether/EtOAc, Rf = 
0.34). 
1
H NMR (CDCl3): 7.51 (d, J = 16.2 Hz, 1H, alkene), 7.38 (d, J = 7.1 Hz, 1H, 
Ar), 7.23-7.30 (m, 3H, Ar and alkene), 7.18 (d, J = 3.3 Hz, 1H, indole), 6.82 (d, J = 
3.1 Hz, 1H, indole), 6.77 (d, J = 2.2 Hz, 2H, Ar), 6.44 (t, J = 2.2 Hz, 1H, Ar), 4.21 (t, 
J = 6.8 Hz, 2H, CH2), 3.88 (s, 6H, 2 x OCH3), 3.30 (t, J = 6.7 Hz, 2H, CH2), 1.97 (m, 
2H, CH2), 1.62 (m, 2H, CH2). 
13
C-NMR (CDCl3): 161.0 (C), 140.0, 136.4, 129.8, 
127.0 (C, Ar), 129.3, 127.9, 121.8, 117.3, 108.8, 104.6, 99.9, 99.7 (CH, Ar and 
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alkene), 55.4 (2 x OCH3), 51.0, 46.0, 27.5, 26.4 (CH2). EI-HRMS (M + H)
+
 found 
377.1975, calculated for C22H25N4O2 377.1972. 
 
5.1.5 General method for the preparation of amines 16 and 17. To a solution of 
azide-1H-indole (14 or 15) (2 mmols) in dry THF (6 mL) was added 
triphenylphosphine (2.4 mmols) and the reaction stirred at room temperature until 
evolution of nitrogen ceased (about 1 h). H2O (0.4 mL, 22 mmols) was added to the 
reaction mixture which was heated at 60˚C for 2 h. The reaction mixture was 
concentrated under reduced pressure. The residue was stirred for 20 min with aqueous 
2 M HCl (20 mL) and then extracted with CH2Cl2 (2 x 20 mL). To the aqueous layer 
was added aqueous 1 M NaOH (50 mL) until basic pH. The aqueous solution  was 
then extracted with EtOAc (2 x 100 mL), dried (MgSO4) and the solvent removed 
under reduced pressure to afford the pure product as a  glue. 
5.1.5.1. 3-(4-Styryl-indol-1-yl)propylamine (16a, R = H). Obtained in 77% yield as 
a yellow glue. TLC (CH2Cl2, Rf = 0.16). 
1
H NMR (CDCl3): 7.61 (d, J = 7.4 Hz, 2H, 
Ar), 7.55 (d, J = 16.3 Hz, 1H, alkene), 7.37-7.43 (m, 3H, Ar), 7.23-7.35 (m, 4H, Ar 
and alkene), 7.21 (d, J = 3.0 Hz, 1H, indole), 6.82 (d, J = 3.0 Hz, 1H, indole), 4.27 (t, 
J = 6.8 Hz, 2H, CH2), 2.75 (t, J = 6.9 Hz, 2H, CH2), 2.02 (m, 2H, CH2), 1.67 (bs, 2H, 
-CH2NH2). 
13
C-NMR (CDCl3): 138.0, 136.4, 129.9, 126.9 (C, Ar), 129.3, 128.5, 
128.1, 127.3, 127.3, 126.4, 121.7, 117.1, 108.8, 99.7 (CH, Ar and alkene), 43.9, 39.3, 
33.7 (CH2). EI-HRMS (M + H)
+
 found 277.1701, calculated for C19H21N2 277.1699. 
5.1.5.2. 3-[4-(3,5-Dimethoxystyryl)-indol-1-yl]propylamine (16b, R = OCH3). 
Obtained in 72% yield as a yellow glue. TLC (1:1 Petroleum ether/EtOAc Rf = 0.15). 
1
H NMR (CDCl3): 7.50 (d, J = 16.2 Hz, 1H, alkene), 7.36 (d, J = 7.2 Hz, 1H, Ar), 
7.21-7.29 (m, 3H, Ar, and alkene), 7.16 (d, J = 3.2 Hz, 1H, indole), 6.81 (dd, Jx,a = 0.8 
Hz, Jx,b = 2.6  Hz, 1H, indole) 6.74 (d, J = 2.3 Hz, 2H, Ar), 6.42 (d, J = 2.3 Hz, 1H, 
Ar), 4.29 (t, J = 6.7 Hz, 2H, CH2),  3.88 (s, 6H, 2 x OCH3), 3.87 (bs, 2H, -CH2NH2), 
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3.29 (t, J = 6.3 Hz, 2H, CH2), 2.11 (m, 2H, CH2). 
13
C-NMR (CDCl3): 161.0 (C), 
140.0, 136.3, 129.8, 127.0 (C, Ar), 129.4, 128.1, 127.7, 121.9, 117.4, 108.7, 104.6, 
100.2, 99.7 (CH, Ar and alkene), 55.4 (2 x OCH3), 48.3, 43.2, 29.3 (CH2). EI-HRMS 
(M + H)
+
 found 337.1911, calculated for C21H25N2O2 337.1911. 
5.1.5.3. 4-(4-Styryl-indol-1-yl)butylamine (17a, R = H). Obtained in 60% yield as a 
yellow glue. TLC (CH2Cl2, Rf = 0.16). 
1
H NMR (CDCl3): 7.61 (d, J = 7.3 Hz, 2H, 
Ar), 7.44-7.58 (m, 4H, Ar and alkene), 7.26-7.35 (m, 4H, Ar and alkene), 7.19 (d, J = 
3.1 Hz, 1H, indole), 6.81 (t, J = 3.1 Hz, 1H, indole), 4.18 (t, J = 6.9 Hz, 2H, CH2), 
2.72 (t, J = 7.0 Hz, 2H, CH2), 1.88-1.94 (m, 4H, CH2, -CH2NH2), 1.49 (m, 2H, CH2). 
13
C-NMR (CDCl3): 138.0, 136.4, 129.9, 127.3 (C, Ar), 129.2, 128.7, 128.4, 128.0, 
127.0, 126.4, 121.6, 117.1, 108.8, 99.6 (CH, Ar and alkene), 46.4, 41.7, 30.9, 27.2 
(CH2). EI-HRMS (M + H)
+
 found 291.1857, calculated for C20H23N2 291.1856. 
5.1.5.4. 4-[4-(3,5-Dimethoxystyryl)-indol-1-yl]butylamine (17b, R = OCH3). 
Obtained in 79% yield as a yellow glue. TLC (1:1 Petroleum ether/EtOAc Rf = 0.16). 
1
H NMR (CDCl3): 7.51 (d, J = 16.2 Hz, 1H, alkene), 7.38 (d, J = 7.1 Hz, 1H, Ar), 
7.23-7.30 (m, 3H, Ar and alkene), 7.17 (d, J = 3.3 Hz, 1H, indole), 6.76 (d, J = 3.1 
Hz, 1H, indole), 6.74 (d, J = 2.2 Hz, 2H, Ar), 6.42 (d, J = 2.3 Hz, 1H, Ar), 4.24 (m, 
2H, CH2), 3.86 (s, 6H, 2 x OCH3), 3.36 (bs, 4H, CH2, -CH2NH2), 1.90 (m, 2H, CH2), 
1.70 (m, 2H, CH2). 
13
C-NMR (CDCl3): 161.0 (C), 133.8, 133.6, 132.0, 131.9 (C, 
Ar), 129.2, 128.1, 127.7, 121.7, 117.3, 108.9, 104.6, 99.8, 99.7 (CH, Ar and alkene), 
55.4 (2 x OCH3), 45.9, 30.3, 28.9, 23.7 (CH2). EI-HRMS (M + H)
+
 found 351.2070, 
calculated for C22H27N2O2 351.2067. 
 
5.1.6 General method for the preparation of benzenesulfonamides 18 and 19. 
Toluenesulfonyl chloride (1 mmol) and indole amine (16 or 17) (1.1 mmol) were 
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dissolved in  dry CH2Cl2 (10 mL) under nitrogen atmosphere. The mixture was 
treated dropwise with triethylamine (2.2 mmol) under ice-cooling and then stirred for 
30 min at 0˚C. On completion, the reaction mixture was washed with aqueous 2 M 
HCl (2 x 30 mL) and with brine (25 mL). Evaporation of the organic solvent after 
drying over MgSO4 gave the crude compound. The product was isolated by flash 
column chromatography or recrystallisation giving the desired compound. 
5.1.6.1. 4-Methyl-N-[3-(4-styryl-indol-1-yl)propyl]benzenesulfonamide (18a, R = 
H). Obtained in 39% yield as a white solid after recrystallisation from ethyl 
acetate/hexane. TLC (CH2Cl2, Rf = 0.30). M.p. 130-132 
o
C. 
1
H-NMR (CDCl3):  7.69 
(d, J = 8.2 Hz, 2H, Ar),  7.60 (d, J = 7.4 Hz, 2H, Ar), 7.53 (d, J = 16.3 Hz, 1H, 
alkene), 7.38-7.42 (m, 3H, Ar), 7.28-7.33 (m, 4H, Ar and alkene), 7.21-7.24 (m, 2H, 
Ar), 7.15 (d, J = 3.1 Hz, 1H, indole), 6.79 (d, J = 3.1 Hz, 1H, indole), 4.45 (t, J= 6.5 
Hz, 1H, -CH2NH-SO2PhCH3), 4.23 (t, J= 6.5 Hz, 2H, CH2), 2.92 (q, J= 6.5 Hz, 2H, 
CH2), 2.43(s, 1H, CH3), 2.04 (m, 2H, CH2). 
13
C-NMR (CDCl3): 143.6, 137.9, 136.4, 
136.2, 130.1, 127.6 (C, Ar), 129.8, 129.4, 128.6, 128.1, 127.4, 127.1, 127.0, 126.5, 
121.9, 117.2, 108.6, 100.1 (CH, Ar and alkene), 43.3, 40.5, 30.0 (CH2), 21.5 (CH3). 
EI-HRMS (M + H)
 +
 found 431.1783, calculated for C26H27N2O2S 431.1788. 
5.1.6.2. N-(3-{4-[2-(3,5-dimethoxy-phenyl)-vinyl]-indol-1yl}-propyl)-4-methyl-
benzenesulfonamide (18b, R = OCH3). A white solid was obtained in 45% yield 
after purification by flash column chromatography (dichloromethane). TLC (CH2Cl2, 
Rf = 0.40). M.p. 142-144 
o
C.  
1
H-NMR (CDCl3):  7.68 (d, J = 8.3 Hz, 2H, Ar), 7.50 
(d, J = 16.4 Hz, 1H, alkene), 7.37 (m, 1H, Ar), 7.28 (d, J = 8.3 Hz, 2H, Ar), 7.24 (d, J 
= 16.4 Hz, 1H, alkene) 7.22 (d, J = 4.4 Hz, 2H, Ar), 7.10 (d, J = 3.1 Hz, 1H, indole), 
6.79 (d, J= 3.3 Hz, 1H, indole), 6.76 (d, J = 2.2 Hz, 2H, Ar), 6.44 (t, J= 2.2 Hz, 1H, 
Ar), 4.44 (t, J= 6.4 Hz, 1H, -CH2NH-SO2PhCH3), 4.23 (t, J = 6.6 Hz, 2H, CH2), 3.88 
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(s, 6H, 2 x OCH3), 2.92 (q, J= 6.5 Hz, 2H, CH2), 2.43 (s, 1H, CH3), 2.04 (m, 2H, 
CH2). 
13
C-NMR (CDCl3): 161.0 (C), 143.6, 139.9, 136.4, 136.2, 129.8, 127.6 (C, 
Ar), 129.8, 129.4, 128.1, 127.6, 127.0, 121.9, 117.4, 108.7, 104.6, 100.1, 99.8 (CH, 
Ar and alkene), 55.4 (2 x OCH3), 43.3, 40.5, 30.0 (CH2), 2.5 (CH3). EI-HRMS (M + 
H)
+
 found 491.1989, calculated for C28H31N2O4S 491.1999. 
5.1.6.3. 4-Methyl-N-[4-(4-styryl-indol-1-yl)butyl]benzenesulfonamide (19a, R = 
H). A yellow glue was obtained in 33% yield after purification by flash column 
chromatography (petroleum ether – ethyl acetate 100:0 v/v increasing to 80:20 v/v). 
TLC (dichloromethane) Rf 0.40. 
1
H-NMR (CDCl3):  7.71 (d, J = 8.2 Hz, 2H, Ar),  
7.61 (d, J = 7.4 Hz, 2H, Ar), 7.53 (d, J = 16.3 Hz, 1H, alkene), 7.36-7.42 (m, 3H, Ar), 
7.28-7.33 (m, 4H, Ar and alkene), 7.23 (d, J = 4.4 Hz, 2H, Ar), 7.11 (d, J = 3.1 Hz, 
1H, indole), 6.79 (d, J = 3.2 Hz, 1H, indole), 4.43 (t, J = 6.3 Hz, 1H, -CH2NH-
SO2PhCH3), 4.13 (t, J = 6.5 Hz, 2H, CH2), 2.92 (q, J = 6.7 Hz, 2H, CH2), 2.43 (s, 1H, 
CH3), 1.87 (m, 2H, CH2), 1.47 (m, 2H, CH2). 
13
C-NMR (CDCl3): 143.5, 137.9, 
136.8, 136.3, 129.9, 126.9 (C, Ar), 129.7, 129.3, 128.6, 127.9, 127.4, 127.2, 127.0, 
126.4, 121.8, 117.1, 108.7, 99.8 (CH, Ar and alkene), 45.8, 42.6, 27.1, 27.1 (CH2), 
21.5 (CH3). EI- HRMS (M + H)
+
 found 445.1944, calculated for C27H29N2O2S 
445.1944. 
5.1.6.4 N-(4-{4-[2-(3,5-dimethoxy-phenyl)-vinyl]-indol-1yl}-butyl)-4-methyl-
benzenesulfonamide (19b, R = OCH3). A yellow glue was obtained in 20% yield 
after purification by flash column chromatography (dichloromethane). TLC 
(dichloromethane) Rf 0.24. 
1
H-NMR (CDCl3):  7.71 (d, J = 8.3 Hz, 2H, alkene), 7.50 
(d, J = 16.3 Hz, 1H, alkene), 7.36 (m, 1H, Ar), 7.22-7.29 (m, 5H, Ar and alkene), 7.11 
(d, J = 3.3 Hz, 1H, indole), 6.78 (d, J = 3.3 Hz, 1H, indole), 6.76 (d, J = 2.1 Hz, 2H, 
Ar), 6.44 (t, J = 2.1 Hz, 1H, Ar), 4.47 (t, J = 6.4 Hz, 1H, -CH2NH-SO2PhCH3), 4.12 
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(t, J = 6.6 Hz, 2H, CH2), 3.87 (s, 6H, 2 x OCH3), 2.92 (dd, Jx,a = 6.6 Hz, Jx,b = 6.8  Hz, 
2H, CH2), 2.42 (s, 1H, CH3), 1.86 (m, 2H, CH2), 1.47 (m, 2H, CH2). 
13
C-NMR 
(CDCl3): 161.0 (C), 143.4, 140.0, 136.8, 136.3, 129.8, 126.9 (C, Ar), 129.7, 129.4, 
128.0, 127.7, 127.0, 121.7, 117.3, 108.8, 104.6, 99.8, 99.7 (CH, Ar and alkene), 55.4 
(2 x OCH3), 45.8, 42.6, 27.1, 27.0 (CH2), 21.5 (CH3). EI-HRMS (M + H)
+
 found 
505.2150, calculated for C29H33N2O4S 505.2156. 
 
5.1.7 Synthesis of (E)-3-(4-styryl-1H-indol-1-yl)propyl benzenesulfinate (20).  To 
a solution of 1-(3-bromopropyl)-4-styryl-1H-indole (4a) (2.9 mmol) in DMF (10 mL) 
was added benzene sulfinic acid sodium salt (2.9 mmol) and the reaction stirred at 
room temperature for 24 h. The reaction mixture was then evaporated in vacuo and 
the residue was dissolved in CH2Cl2 (100 mL), extracted with H2O (2 x 50 mL) and 
dried over MgSO4. The organic layer was reduced in vacuo and the crude compound 
was purified by column chromatography (petroleum ether-EtOAc 100:0 v/v 
increasing to 70:30 v/v) giving a yellow oil in 53% yield. TLC (petroleum ether – 
EtOAc 7:3 v/v) Rf 0.29. 
1
H-NMR (CDCl3):  7.87 (d, J = 8.2 Hz, 2H, Ar), 7.63 (m, 
1H, Ar), 7.60 (d, J = 7.5 Hz, 2H, Ar), 7.51-7.55 (m, 3H, Ar and alkene), 7.38-7.41 (m, 
3H, Ar), 7.27-7.32 (m, 2H, Ar and alkene), 7.22 (m, 2H, Ar), 7.15 (d, J = 3.2 Hz, 1H, 
indole), 6.81 (d, J = 3.2 Hz, 1H, indole), 4.32 (t, J = 6.7 Hz, 2H, CH2), 3.01 (t, J = 6.9 
Hz, 2H, CH2), 2.32 (m, 2H, CH2). 
13
C-NMR (CDCl3): 138.9, 137.8, 136.3, 130.1, 
129.3, 127.0 (C, Ar), 133.8, 129.5, 128.6, 127.9, 127.7, 127.4, 127.1, 126.5, 122.1, 
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117.3, 108.6, 100.5 (CH, Ar and alkene), 60.3, 53.0, 44.3 (CH2). EI-HRMS (M + H)
+
  
found 402.1523, calculated for C25H24NO2S 402.1522.  
 
5.1.8 General method for the preparation of the ethyl esters (21).  The styryl 
indole derivatives (3) (4.3 mmol) and NaH  (60% dispersion in mineral oil) (12.9 
mmol) in dry DMF (20 mL) were cooled to 0˚C using an ice bath and stirred for 5 
min. Ethyl-3-bromopropionate (12.9 mmol) was added and the reaction mixture was 
stirred for 2 h at room temperature. On completion, the solvent was evaporated under 
reduced pressure and the residue was dissolved in CH2Cl2 (100 mL), washed with 
H2O (2 x 50 mL) and dried over MgSO4. The organic layer was then evaporated to 
dryness. 
5.1.8.1 3-(4-Styryl-indol-1-yl)-propionic acid ethyl ester (21a, R = H).  A yellow 
oil was obtained in 60% yield after purification by flash column chromatography 
(petroleum ether then CH2Cl2). TLC (CH2Cl2) Rf 0.83. 
1
H-NMR (CDCl3):  7.64 (d, J 
= 7.7 Hz, 2H, Ar), 7.59 (d, J = 16.2 Hz, 1H, alkene), 7.42-7.45 (m, 3H, Ar), 7.29-7.37 
(m, 4H, Ar and alkene), 7.26 (d, J = 3.2 Hz, 1H, indole), 6.85 (d, J = 3.2 Hz, 1H, 
indole), 4.59 (t, J = 6.9 Hz, 2H, CH2), 4.18 (q, J = 7.2 Hz, 2H, CH2), 3.34 (t, J = 6.1 
Hz, 2H, CH2), 2.87 (t, J = 6.9 Hz, 2H, CH2), 1.26 (t, J = 7.2 Hz, 3H, CH3). 
13
C-NMR 
(CDCl3):   171.1 (C), 137.9, 136.1, 130.0, 127.1 (C, Ar), 129.4, 128.6, 128.2, 
127.4, 127.1, 126.5, 121.9, 117.5, 117.3, 108.5, 101.3, 100.2 (CH, Ar and alkene), 
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60.9, 42.0, 35.0 (CH2), 14.1 (CH3). EI-HRMS (M + H)
+
 found 320.1648, calculated 
for C21H22NO2 320.1645.  
5.1.8.2 3-{4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-indol-1-yl}-propionic acid ethyl 
ester (21b, R = OCH3). A yellow oil was obtained in 53% yield after purification by 
flash column chromatography (petroleum ether then CH2Cl2). TLC (CH2Cl2) Rf 0.71. 
1
H-NMR (CDCl3):  7.52 (d, J = 16.3 Hz, 1H, alkene), 7.39 (d, J = 7.2 Hz, 1H, Ar), 
7.30-7.36 (m, 2H, Ar and alkene), 7.27 (d, J = 7.2 Hz, 1H, Ar), 7.24 (d, J = 3.2 Hz, 
1H, indole), 6.81 (d, J = 3.1 Hz, 1H, indole), 6.78 (d, J = 2.0 Hz, 2H, Ar), 6.45 (t, J = 
2.0 Hz, 1H, Ar), 4.50 (t, J = 6.9 Hz, 2H, CH2), 4.15 (q, J = 7.2 Hz, 2H, CH2) , 3.88 (s, 
6H, 2 x OCH3), 2.86 (t, J = 6.9 Hz, 2H, CH2), 1.24 (t, J = 7.2 Hz, 3H, CH3). 
13
C-NMR 
(CDCl3): 171.1 (C), 161.0 (C), 140.0, 136.1, 129.8, 127.1 (C, Ar), 129.3, 128.3, 
127.7, 121.9, 117.4, 108.7, 104.6, 100.1, 99.7 (CH, Ar and alkene), 55.4 (2 x OCH3), 
60.9, 42.0, 35.0 (CH2), 14.1 (CH3). EI-HRMS (M + H)
+
 found 380.1859, calculated 
for C23H26NO4 380.1856.  
 
 
5.1.9 General method for the preparation of 3- styryl indole propanol derivatives 
(22).  A solution of 3-ethyl styryl indole propionate derivative (21) (2.1 mmol) in dry 
THF (12 mL) under nitrogen atmosphere was cooled to 0˚C. LiAlH4 (1M solution in 
THF) (8.4 mmol) was added dropwise via syringe. The yellow reaction mixture was 
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stirred at 0˚C for 1 h, then at room temperature for 4 h. The reaction was quenched by 
the addition of EtOAc (70 mL), the organic layer was washed with H2O (3 x 50 mL), 
dried over MgSO4, and evaporated to dryness. 
5.1.9.1 3-(4-Styryl-indol-1-yl)-propan-1-ol (22a, R = H). A yellow-orange wax was 
obtained in 20% after purification by flash column chromatography (CH2Cl2). TLC 
(CH2Cl2) Rf 0.28. 
1
H-NMR (CDCl3):  7.61 (d, J = 7.3 Hz, 2H, Ar), 7.56 (d, J = 16.5 
Hz, 1H, alkene), 7.39-7.42 (m, 3H, Ar), 7.35 (d, J = 7.4 Hz, 2H, Ar), 7.24-7.31 (m, 
3H, Ar and alkene), 7.23 (d, J = 3.2 Hz, 1H, indole), 6.83 (d, J = 3.2 Hz, 1H, indole), 
4.33 (t, J = 6.8 Hz, 2H, CH2) , 3.64 (t, J = 5.8  Hz, 2H, CH2), 2.10 (m, 2H, CH2), 1.37 
(bs, 1H, -CH2OH). 
13
C-NMR (CDCl3):   138.0, 136.5, 129.9, 127.0 (C, Ar), 129.3, 
128.6, 128.2, 127.3, 127.2, 126.4, 121.7, 117.1, 108.8, 99.8 (CH, Ar and alkene), 
59.5, 42.8, 32.6 (CH2). EI-HRMS (M + H)
+
 found 278.1539, calculated for C19H20NO 
278.1539. 
5.1.9.2 3-{4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-indol-1-yl}-propan-1-ol (22b, R = 
OCH3). A brownish wax was obtained in 48% yield after purification by flash 
column chromatography (CH2Cl2-MeOH 100:0 v/v increasing to 98:2 v/v). TLC 
(CH2Cl2) Rf 0.20. 
1
H-NMR (CDCl3):  7.52 (d, J = 16.4 Hz, 1H, alkene), 7.34-7.38 
(m, 2H, Ar), 7.22-7.27 (m, 3H, Ar, alkene and indole), 6.81 (d, J = 3.1 Hz, 1H, 
indole), 6.77 (d, J = 2.1 Hz, 2H, Ar), 6.44 (t, J = 2.1 Hz, 1H, Ar), 4.33 (t, J = 6.7 Hz, 
2H, CH2), 3.88 (s, 6H, 2 x OCH3), 3.63 (t, J = 5.9 Hz, 2H, CH2), 2.10 (m, 2H, CH2), 
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1.65 (bs, 1H, -CH2OH). 
13
C-NMR (CDCl3): 161.0 (C), 140.0, 136.5, 129.7, 126.9 
(C, Ar), 129.2, 128.3, 127.7, 121.7, 117.3, 108.9, 104.6, 99.7, 99.6 (CH, Ar and 
alkene), 55.4 (2 x OCH3), 59.4, 42.8, 35.6 (CH2). EI-HRMS (M + H)
+
 found 
338.1755, calculated for C21H24NO3 338.1751.  
 
5.1.10 General method for the synthesis of toluene-sulfonic acid 3-styryl indole 
propyl ester derivatives (23). To a cooled (0˚C) solution of  3-styryl indole propanol 
derivative (22) (0.9 mmol) and 4-dimethylaminopyridine (0.2 mmol) in dry CH2Cl2 (7 
mL) and pyridine (0.7 mL) under nitrogen atmosphere was added 4-toluenesulfonyl 
chloride (2 mmol) portion-wise. The reaction was stirred at 0˚C for 10 min then 
stirred for 24 h at room temperature. On the completion, the reaction mixture was 
washed with aqueous satured NaHCO3 (50 mL) and the organic layer was separated. 
The aqueous layer was extracted with CH2Cl2 (50 mL) and both organic layers were 
washed with aqueous 1 M HCl (50 mL). The organic layer was washed with aqueous 
saturated NaHCO3 (50 mL) and then dried over MgSO4. The solvent was evaporated 
under vacuum. 
5.1.10.1 Toluene-4-sulfonic acid 3-(4-styryl-indol-1-yl)-propyl ester (23a, R = H). 
A yellow glue was obtained in 53% yield after purification by flash column 
chromatography (petroleum ether – ethyl acetate 100:0 v/v increasing to 90:10 v/v). 
TLC (petroleum ether – ethyl acetate 8:2 v/v) Rf 0.48. 
1
H-NMR (CDCl3):  7.78 (d, J 
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= 8.2 Hz, 2H, Ar), 7.60 (d, J = 7.1 Hz, 2H, Ar), 7.52 (d, J = 16.4 Hz, 1H, alkene), 
7.29-7.42 (m, 7H, Ar and alkene), 7.20-7.24 (m, 3H, Ar), 7.04 (d, J = 3.2 Hz, 1H, 
indole), 6.74 (d, J = 3.2 Hz, 1H, indole), 4.26 (t, J = 6.5 Hz, 2H, CH2) , 3.99 (t, J = 5.5  
Hz, 2H, CH2), 2.47 (s, 3H, CH3), 2.20 (m, 2H, CH2). 
13
C-NMR (CDCl3):   145.0, 
139.9, 136.1, 132.7, 130.0, 127.0 (C, Ar), 129.9, 129.4, 128.6, 128.1, 127.9, 127.4, 
127.1, 126.4, 121.9, 117.2, 108.5, 100.1 (CH, Ar and alkene), 67.0, 42.2, 29.4 (CH2), 
21.6 (CH3). EI-HRMS (M + H)
+
 found 432.1627, calculated for C26H26NO3S 
432.1628.  
5.1.10.2 Toluene-4-sulfonic acid 3-{4-[2-(3,5-dimethoxy-phenyl)-vinyl]-indol-1-
yl}-propyl ester (23b, R = OCH3). A yellow-orange glue was obtained in 50% yield 
after purification by flash column chromatography (petroleum ether – ethyl acetate 
100:0 v/v increasing to 80:20 v/v). TLC (petroleum ether – ethyl acetate 1:1 v/v) Rf 
0.57. 
1
H-NMR (CDCl3):  7.78 (d, J = 8.2 Hz, 2H, Ar), 7.48 (d, J = 16.5 Hz, 1H, 
alkene), 7.33-7.37 (m, 3H, Ar), 7.21-7.24 (m, 3H, Ar and alkene), 7.04 (d, J = 3.1 Hz, 
1H, indole), 6.76 (d, J = 2.2 Hz, 2H, Ar), 6.74 (d, J = 3.1 Hz, 1H, indole), 6.44 (t, J = 
2.2 Hz, 1H, Ar), 4.26 (t, J = 6.6 Hz, 2H, CH2),  3.99 (t, J = 5.7 Hz, 2H, CH2), 3.88 (s, 
6H, 2 x OCH3), 2.47 (s, 3H, CH3), 2.04 (m, 2H, CH2). 
13
C-NMR (CDCl3): 161.0 
(C), 145.0, 139.9, 136.1, 132.7, 129.8, 127.6 (C, Ar), 129.9, 129.4, 128.1, 27.9, 127.1, 
121.9, 117.4, 108.6, 104.6, 100.1, 99.7 (CH, Ar and alkene), 55.4 (2 x OCH3), 67.0, 
42.2, 29.4 (CH2), 21.6 (CH3). EI-HRMS (M + H)
+
 found 492.1831, calculated for 
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C28H30NO5S 492.1839.  
 
5.2 CYP24A1 and CYP27B1 inhibition assay  
Inhibition of CYP24A1 was carried out as described previously [23].
 
Briefly, 
reaction mixture containing 0.1 μM each of Adx and AdR, 0.075 μM MBP-
CYP24A1, 2.5 μM 1,25(OH)2D3, varying concentrations of inhibitors, and 0.5 mM 
NADPH was incubated at 37 °C for 25 min in a buffer of 20 mM Tris (pH 7.5) and 
125 mM NaCl. All inhibitors were dissolved in ethanol (>10 mM) or DMSO (>50 
mM) and further diluted in ethanol to make working stock (<1 mM). The reaction was 
extracted with CH2Cl2 and analyzed by HPLC. The IC50 values were determined by 
fitting the relative activity (V/V0) against the inhibitor concentration [I] using the 
equation V/V0 = IC50/(IC50 + [I]), where V and V0 are the reaction rates in the 
presence and absence of inhibitors. The assay for each compound was performed in at 
least duplicate and in triplicate for compounds with good inhibitory properties. 
The KI values were calculated using equation KI = IC50/(1 + [S]/KM), where 
[S] is the substrate concentration and KM = 0.19 μM [14]. 
Inhibition assay of CYP27B1 was performed in a similar way to that of 
CYP24A1 as previously described [23]. The concentration of substrate 25(OH)D3 was 
2.5 μM and KM for CYP27B1 was 0.48 μM. 
 
5.3 Molecular Modelling 
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT 
[29]. The important amino acid residues of the active pocket (Gln82, Ile131, Trp134, 
Met246, Ala326, Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500) 
[32] were selected and then the selection was extended to 12 Å in order to include in 
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the docking site the haem iron region and the access tunnel to the catalytic site. A 
ligands database in mol2 format, prepared using MOE [30], was used as input for the 
docking calculations. The iron atom of the catalytic site was set as essential 
pharmacophoric feature. Ligand docking was performed using the default values and 
no water molecules were considered. Ten output solutions were obtained from each 
compound and visual inspection in MOE was used to identify the interaction between 
ligand and protein.  
The flexible alignment studies were performed using MOE 2010. The MOE flexible 
alignment tool generates different possible conformations for each of the different six 
molecules present in the input mol2 format database that could overlap with the 
assigned template. The quality of the alignment is evaluated by a score which is a sum 
of the internal strain of the obtained conformation (the smaller, the better) and the 
overlap of molecular features (aromatic regions, donors/acceptors). MOE, for each 
alignment performed, evaluates the average internal energy of the ligands U, the 
similarity score F (the lower value is the better two structures overlap) and the value S 
(sum of U and F values obtained for each alignment). A good alignment should 
present a dU value (the average strain energy of the molecules in the alignment in 
kcal/mol) lower than 1 kcal/mol meaning that the obtained conformation are not 
energetically disadvantaged. In our case, we kept our template rigid and the flexible 
alignment of the six compounds was run. The obtained data with a dU of 0.0 (no 
energy penalty) were kept and ranked according to the lowest S value.  
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